Delivering Ribonucleic Acid Vaccines Using Nanoparticles
Nicholas Fischer | 20-ERD-004
Executive Summary
We aim to design a versatile nanoplatform for the development and delivery (into the bodies of patients) of nucleic acid-based therapeutics with specially encoded proteins that promote the production of vaccine antigens. If successful, this platform would reduce the time from concept to administration of the therapeutic from months to days, providing a powerful defense against biological threats and disease.
Publications, Presentations, and Patents
He, Wei, Evans, Angela C., Rasley, Amy, Bourguet, Feliza, Peters, Sandra, Kamrud, Kurt I., Wang, Nathaniel, Hubby, Bolyn, Felderman, Martina, Gouvis, Heather, Coleman, Matthew A., Fischer, Nicholas O. 2020. “Cationic HDL mimetics enhance in vivo delivery of self-replicating mRNA.” Nanomedicine: Nanotechnology, Biology and Medicine 24: 102154. https://doi.org/10.1016/j.nano.2020.102154.
He, Wei, Amy Rasley, Sean F. Gilmore, Sandra Peters, Matthew A. Coleman, and Nicholas O. Fischer. "Tailoring HDL mimetics for in vivo delivery of mRNA." In American Society for Biochemistry and Molecular Biology Annual Meeting. 2020.
Fischer, Nicholas O. "Designing HDL mimetic nanoparticles for in vivo delivery." In American Chemical Society Fall Meeting. 2020.
Fischer, Nicholas O. "Tailoring HDL mimetics for vaccine applications." In Amphiphilic Biomarkers: Discovery, Detection, Measurement, Modeling, and Use: Virtual Mini-Conference at Los Alamos National Laboratory. 2020.
Fischer, Nicholas O. "Tailoring HDL mimetics for vaccine applications." In UC Davis College of Biological Sciences Biophysics Graduate Group Seminar Series. 2020.
